Spain’s Liberbank sells 85 pct of Telecable to Carlyle Group


MADRID Oct 18 (Reuters) - Spanish savings bank Liberbank said on Tuesday it has agreed to sell 85 percent of telecommunications company Telecable to the Carlyle Group, cutting the bank’s stake to 15 percent.No financial details of the sale were provided.On Monday, a source told Reuters that Liberbank planned to raise capital by selling an approximately 70 percent stake in Telecable worth about 300 million euros.Spain has forced its banks — laden with bad debt after a housing bubble burst in 2008 — to merge and raise capital or be taken over by the government.Banks without significant private investment must meet a 10 percent core tier 1 capital ratio.Liberbank, formed by the merger of regional savings banks Cajastur, Caja Extremadura and Caja Cantabria, initially required about 519 million euros to reach the 10 percent target, but had cut this back to about 200 million euros by generating capital organically, the source said on Monday.The Bank of Spain gave Liberbank and one other bank, Banco Mare Nostrum (BMN) more time to raise funds.BMN plans to issue 250 million euros of convertible bonds to meet the central bank’s tough new capital requirements, a source close to the deal said on Monday.

Analysis: As patients put up with pain, device sales suffer


As it gets harder for them to walk, some find hip or knee replacement surgery a compelling option. But many of Tongue’s patients have another worry, one that is causing some to delay treatment and live with the pain awhile longer.”We have more people who are anxious about losing their jobs if they have elective surgery. They are anxious about returning to work,” said Tongue, who practices near Portland, Oregon, referring to the time they would need to take off to recuperate. He does up to 400 procedures a year.With 14 million Americans searching for work, lack of health insurance is one reason some people are putting off medical procedures such as joint surgery.For those who do have jobs and insurance, the fear of being expendable at work combined with sticker shock from rising out-of-pocket expenses is a deterrent to getting care. Some older patients are even waiting until they are eligible for the government-funded Medicare program at the age of 65.”They are concerned about higher deductibles and costs. They want more information about what their total bill will be if they have the procedure,” Tongue said. “We’re seeing people trying to put things off until they get to Medicare, with the impression that they will have a lower cost.”As the economy struggles to avoid recession, sales of medical devices such as artificial hips and knee joints are expected to remain sluggish into next year.The new projections confound expectations by companies that had bet a recovery would come earlier, on the assumption that patients could not wait too long for treatment. Some could reset their forecasts as they report quarterly financial results, starting this week, analysts said.”People are putting off any sort of non-acute, nonsymptomatic care. Even if it is symptomatic, until it becomes acute they are not taking the time to come in,” said Morningstar analyst Debbie Wang. “Especially if unemployment stays at 9 percent, a lot of folks are going to clench their teeth and ignore the pain.”A “NEW NORMAL” FOR HEALTHCARE?Some analysts have scaled back growth forecasts for the big orthopedic and cardiac device makers in recent days, throwing in the towel on hopes for a modest pickup in demand next year.A report by Ernst & Young last month cited a “new normal” for the medical device industry, extending a term more often tied to credit card use or discretionary shopping patterns. In healthcare, that shift is partly based on patients turning down treatment when they question its necessity.New U.S. government and congressional investigations into unnecessary procedures, as well as patient complaints, incomplete safety data and several high-profile device recalls, have also grabbed media headlines in the last two years.”We no longer expect a procedural rebound in 2012,” said Mizuho Securities analyst Michael Matson. “Analysts’ estimates still assume some sort of recovery next year, and that isn’t going to happen.”Matson cut his forecast for hip and knee procedure growth in 2012 to 1 percent from his prior expectation for growth of 3 percent, a field led by Johnson & Johnson, Stryker Corp and Zimmer Holdings.For the spine device market — a major business for Medtronic Inc and others — he now expects flat volume next year, down from his previous forecast for slight growth of 1 percent.The slowdown is being felt beyond orthopedics, in specialties ranging from urology to cardiology.Morningstar’s Wang expects volumes in one of the industry’s top markets — implanted heart defibrillators — to decline by 2 percent to 4 percent, affecting Medtronic and rivals Boston Scientific Corp and St Jude Medical Inc, two large healthcare companies with significant device businesses, as well as Intuitive Surgical Inc, Stryker, St Jude, Boston Scientific and Baxter International Inc all report quarterly earnings this week.Expectations for many medical technology companies in the third quarter have already been lowered to reflect the ongoing weakness in surgical procedure volumes, with the focus now turning to companies’ projections for 2012.According to research from J.P. Morgan, which keeps a database of 8,000 U.S. physicians, office visits in September declined 8 percent from a year ago, following a 7 percent drop in August and a 4 percent slump in July.Visits in the third quarter fell to the lowest level since the bank began collecting data in the first quarter of 2008 and mirror a drop-off in U.S. consumer confidence.Device makers are also under pressure with the implementation of a U.S. healthcare overhaul, which is expected to bring cuts to Medicare reimbursement rates for hospitals.That means doctors and other healthcare providers are likely to take an even harder line on the pricing and use of medical technology.With an aging population and more baby boomers approaching retirement age, physicians and analysts alike believe some bounceback in procedures is inevitable.”If you need a hip replaced, you are going to get a hip replaced eventually. Otherwise you are going to be in a wheelchair,” said Morgan Keegan & Co analyst Jan Wald.”I don’t think this is a secular trend that is going to impact the markets forever. When the economy comes back, we’ll see a pickup,” Wald said.The timing, however, continues to elude industry watchers.”Historically it was not the case that this group was tied to the economy, but they definitely are now,” said Leerink Swann analyst Rick Wise.

No deal yet on Thales/Safran asset swap - sources


By Tim HepherPARIS, Oct 13 (Reuters) - French state-controlled companies Thales and Safran need more time to conclude a government-backed deal to swap defence assets as they try to overcome differences over valuation, sources familiar with the matter said on Thursday.The sources denied a French media report that the long-awaited deal, which bankers estimate to be worth around 400 million euros ($552 million), was ready to be announced on Friday.”The discussions are continuing, but there is no agreement yet,” a source familiar with the discussions told Reuters.Thales and Safran declined to comment.For more than a year the two companies have been under pressure from the French government to streamline their investments in optronics and avionics to avoid strains on the national defence budget.France’s arms procurement agency funds parallel development work at both companies and wants them to rationalize their assets to remove the need for duplication.Earlier attempts to reach a deal failed last year when talks broke down with neither side willing to compromise.But one French defence source said that following the most recent set of contacts the rationale for the move was now more widely accepted, leaving valuation as the main stumbling block.The deal is expected to group the two companies’ electrical power generation systems and navigation activities — including automated flight functions — in Safran.The optronics businesses, which combine electronics and optics, would be brought together under Thales, which is Europe’s largest defence electronics firm.Talks resumed in May but with several companies competing for a slice of dwindling spending in France’s fragmented defence sector, there have been several false starts.Dassault Aviation , a major shareholder in Thales, said in May a deal could be weeks away, but the chief executive of Thales warned negotiations had a “way to go”.Analysts have said the background for co-operation between Thales and Safran, which once considered merging, was brightened by last month’s $16.5 billion deal for U.S. conglomerate United Technolgies to buy Goodrich .Safran and United Technolgies both own important aircraft engine makers and Thales and Goodrich make aircraft systems. ($1=0.725 euros)